Soluble ST2 (sST2) is a novel biomarker implicated in myocardial remodelling and fibrosis. Recent studies in normal subjects have suggested the biological variability (BV) of sST2 is significantly lower than that of the Btype natriuretic peptides, BNP & NTproBNP. It may, consequently, be a better biomarker for monitoring patients with chronic heart failure (CHF). To date, no published studies have examined the BV of sST2 in a heart failure population.
recently been identified as a novel biomarker for cardiac remodelling and fibrosis. Raised concentrations are known to be predictive of mortality in patients with acutely decompensated heart failure (ADHF) [1] [2] [3] . Moreover, several studies have provided evidence for the prognostic role of serial measures of sST2 in patients with ADHF [4] [5] [6] . The role of sST2 in CHF is, however, less well defined 7, 8 . Recently, Wu et al 9 ,, have demonstrated that the RCV of sST2 in healthy volunteers to be much lower than that of BNP or NTproBNP, indicating it may be a better marker for serial monitoring. Despite such promising results, it is likely that variation amongst patients with disease will be greater than that in healthy individuals. To date, no studies analysing the BV or RCV of sST2 in CHF have been reported.
Methods
Fifty patients with CHF, New York Heart Association (NYHA) Class I-III and left ventricular EF ≤40% were recruited from the heart failure clinics at Kings College Hospital, London. A subset of this cohort has been previously described 10 . All were on optimum tolerated heart failure medications. Target dose levels were defined according to current guidelines 11 . Main exclusion criteria were an acute cardiovascular admission or change in prognostically indicated medication within 4 weeks of recruitment, a planned cardiovascular admission, significant renal impairment (estimated glomerular filtration rate (eGFR) <20), or the inability or unwillingness to consent.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Clinical review and blood sampling took place at 5 time pointsbaseline, 1 hour, 1 month, 3 months and 6 months. Reviews took place at the same time of day for each visit. Vital signs and NYHA class were recorded together with medications and details of any hospital admissions. were not normally distributed, data was log transformed prior to analysis. 
Analytical coefficient of variation (CV

Discussion
This is the first reported study assessing and directly comparing the BV and RCVs of sST2 with NTproBNP in a stable CHF population. In contrast to NTproBNP, sST2 does not exhibit significant variation either in the short or long term with RCVs for sST2 ranging from 31% to 47%, compared with 52%
to 128% for NTproBNP.
The implications of these results are clear, especially when taken in conjunction with previously reported data. Studies have shown that standard heart failure therapies reduce average NTproBNP and BNP by up to 50% [12] [13] [14] [15] [16] , whilst reductions in sST2 >50% have been shown to be indicative of therapeutic success of heart failure therapy 17 . Thus, based on the results obtained in this study, a reduction of 50% in NTproBNP cannot be attributed to a therapeutic intervention alone, as this reduction is less than the RCV. In contrast, the same changes in sST2 would be above that of the observed M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
8 RCV and thus more likely due to clinical intervention than variability alone. sST2 may therefore be better than NTproBNP for serial monitoring to guide therapy.
Questions remain, however, as to the exact pathophysiological process such changes in sST2 represent. Although there is much evidence to support its use as a marker of fibrosis, studies also indicate that it plays a vital role in immune modulation and inflammatory responses [18] [19] [20] . In the shorter-term, changes in sST2 may therefore reflect other underlying processes associated with decompensation -such as infection and renal dysfunction. Like CHF, chronic kidney disease (CKD) is a multifactorial disorder, occurring in the context of chronic co-morbid conditions, many of which are related to inflammation and inflammatory responses. sST2 has previously been shown to be associated with disease severity in CKD 21 and variations in renal function across the time points measured could arguably influence the observed BV.. This study was insufficiently powered to account for such variables but, repeated calculations performed after the removal of any patients exhibiting a >25% change in creatinine did not result in a significant change in median CV I or RCV (data not shown).
Several issues including pre-analytic factors, analytical variability and biological variability all contribute to total variability. In order to minimise preanalytic factors we adopted strict entry criteria in order to establish stability at baseline. This is reflected by the low median values that, in the case of sST2, did not exceed the normal reference range. In addition, patient preparation and blood collection protocol was standardised across the group. Blood samples were stored and assays performed in the minimum number of Under these conditions, it is estimated that the assay imprecision will add only 10% to the BV. In our study the CV A of sST2 was 48% of CV I at 1 hour, 40%
at 1 month, 39% at 3 months and 29% at 6 months. For NTproBNP CV A was 23% of CV I at 1 hour, 11% at 1 month, 10% at 3 months and 9% at 6 months. 
